PortalPublikationenResiquimod, a topical drug for viral skin lesions and skin c...

Resiquimod, a topical drug for viral skin lesions and skin cancer.

Standard

Resiquimod, a topical drug for viral skin lesions and skin cancer. / Meyer, Thomas; Surber, Christian; French, Lars E; Stockfleth, Eggert.

in: EXPERT OPIN INV DRUG, Jahrgang 22, Nr. 1, 1, 2013, S. 149-159.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Meyer, T, Surber, C, French, LE & Stockfleth, E 2013, 'Resiquimod, a topical drug for viral skin lesions and skin cancer.', EXPERT OPIN INV DRUG, Jg. 22, Nr. 1, 1, S. 149-159. <http://www.ncbi.nlm.nih.gov/pubmed/23205468?dopt=Citation>

APA

Meyer, T., Surber, C., French, L. E., & Stockfleth, E. (2013). Resiquimod, a topical drug for viral skin lesions and skin cancer. EXPERT OPIN INV DRUG, 22(1), 149-159. [1]. http://www.ncbi.nlm.nih.gov/pubmed/23205468?dopt=Citation

Vancouver

Meyer T, Surber C, French LE, Stockfleth E. Resiquimod, a topical drug for viral skin lesions and skin cancer. EXPERT OPIN INV DRUG. 2013;22(1):149-159. 1.

Bibtex

@article{7aa9588a32784c72b4ebca602cf70520,
title = "Resiquimod, a topical drug for viral skin lesions and skin cancer.",
abstract = "Resiquimod is an immune response modifier which stimulates cells through a toll-like receptors (TLR) 7 and 8 dependent pathway resulting in activation of immune responses that are effective against viral and tumor lesions.",
keywords = "Animals, Humans, Treatment Outcome, Administration, Topical, Skin Diseases/*drug therapy, Antiviral Agents/*administration & dosage/adverse effects/pharmacokinetics, Antineoplastic Agents/*administration & dosage/adverse effects/pharmacokinetics, Imidazoles/*administration & dosage/adverse effects/pharmacokinetics, Virus Diseases/*drug therapy, Animals, Humans, Treatment Outcome, Administration, Topical, Skin Diseases/*drug therapy, Antiviral Agents/*administration & dosage/adverse effects/pharmacokinetics, Antineoplastic Agents/*administration & dosage/adverse effects/pharmacokinetics, Imidazoles/*administration & dosage/adverse effects/pharmacokinetics, Virus Diseases/*drug therapy",
author = "Thomas Meyer and Christian Surber and French, {Lars E} and Eggert Stockfleth",
year = "2013",
language = "English",
volume = "22",
pages = "149--159",
journal = "EXPERT OPIN INV DRUG",
issn = "1354-3784",
publisher = "informa healthcare",
number = "1",

}

RIS

TY - JOUR

T1 - Resiquimod, a topical drug for viral skin lesions and skin cancer.

AU - Meyer, Thomas

AU - Surber, Christian

AU - French, Lars E

AU - Stockfleth, Eggert

PY - 2013

Y1 - 2013

N2 - Resiquimod is an immune response modifier which stimulates cells through a toll-like receptors (TLR) 7 and 8 dependent pathway resulting in activation of immune responses that are effective against viral and tumor lesions.

AB - Resiquimod is an immune response modifier which stimulates cells through a toll-like receptors (TLR) 7 and 8 dependent pathway resulting in activation of immune responses that are effective against viral and tumor lesions.

KW - Animals

KW - Humans

KW - Treatment Outcome

KW - Administration, Topical

KW - Skin Diseases/drug therapy

KW - Antiviral Agents/administration & dosage/adverse effects/pharmacokinetics

KW - Antineoplastic Agents/administration & dosage/adverse effects/pharmacokinetics

KW - Imidazoles/administration & dosage/adverse effects/pharmacokinetics

KW - Virus Diseases/drug therapy

KW - Animals

KW - Humans

KW - Treatment Outcome

KW - Administration, Topical

KW - Skin Diseases/drug therapy

KW - Antiviral Agents/administration & dosage/adverse effects/pharmacokinetics

KW - Antineoplastic Agents/administration & dosage/adverse effects/pharmacokinetics

KW - Imidazoles/administration & dosage/adverse effects/pharmacokinetics

KW - Virus Diseases/drug therapy

M3 - SCORING: Journal article

VL - 22

SP - 149

EP - 159

JO - EXPERT OPIN INV DRUG

JF - EXPERT OPIN INV DRUG

SN - 1354-3784

IS - 1

M1 - 1

ER -